Zimmer Biomet Holdings Inc
ZBH
ISIN null / Valor 1262932
Zimmer Biomet Holdings Inc
UMushroom community rating:
About company
Zimmer Biomet Holdings Inc is a global leader in musculoskeletal healthcare, providing a comprehensive range of products and services to help healthcare professionals treat patients suffering from joint disorders and other orthopedic conditions. The company offers a wide variety of innovative solutions, including joint replacement implants, surgical tools, and biologics, to improve patient outcomes and enhance quality of life. With a strong focus on research and development, Zimmer Biomet is dedicated to advancing the field of orthopedics and delivering cutting-edge technologies to meet the evolving needs of healthcare providers and patients worldwide.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (09.09.2025):
Zimmer Biomet Holdings Inc reported its financial results for the second quarter of 2025, showcasing a robust increase in net sales and earnings per share. The company also provided updated guidance for the full year, reflecting its confidence in continued growth.
Revenue Growth
Second quarter net sales reached $2.077 billion, marking a 7.0% increase on a reported basis, 5.4% on a constant currency1 basis, and 2.8% on an organic constant currency1 basis compared to the prior year period.
Earnings Per Share
The second quarter diluted earnings per share were $0.77, while adjusted diluted earnings per share rose by 3.0% to $2.07.
Updated Full-Year Guidance
Zimmer Biomet has tightened its full-year 2025 revenue growth guidance to 6.7% - 7.7% reported, 6.2% - 7.2% constant currency1, and 3.5% - 4.5% organic constant currency1. Additionally, the company has increased its adjusted1 earnings per share guidance to between $8.10 and $8.30.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
20190 M
Market cap (USD)
1,158,906
Daily traded volume (Shares)
106.22 / 104.7
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Federico Ferrari
EQUITIES OF THE SAME SECTOR
